Yang Connie L, Zysman-Colman Zofia, Chétrit Estelle, Hicks Anne, Reisman Joseph, Glicksman Amy
Canadian Paediatric Society, Respiratory Health Section, Ottawa, Ontario, Canada.
Paediatr Child Health. 2024 Apr 5;29(2):122-132. doi: 10.1093/pch/pxae006. eCollection 2024 May.
This practice point summarizes recommendations from the Canadian Thoracic Society's 2021 "Guideline update: Diagnosis and management of asthma in preschoolers, children, and adults." New recommendations include: a decrease in the frequency of daytime symptoms and reliever use to ≤2 per week in the asthma control criteria; assessing for risk of asthma exacerbation; not using as-needed short-acting beta-agonists alone in patients at higher risk for exacerbation; and the option of as-needed budesonide/formoterol (bud/form) in those ≥12 years old if they are unable to take daily inhaled corticosteroids despite extensive asthma education and support. The preference for daily inhaled corticosteroids to manage mild asthma in children, and the recommendation against intermittent short courses of inhaled corticosteroids, are unchanged.
本实践要点总结了加拿大胸科学会2021年《指南更新：学龄前儿童、儿童及成人哮喘的诊断与管理》中的建议。新建议包括：在哮喘控制标准中，将日间症状频率和缓解药物使用频率降至每周≤2次；评估哮喘加重风险；对于加重风险较高的患者，不单独按需使用短效β受体激动剂；对于≥12岁、尽管接受了广泛的哮喘教育和支持仍无法使用每日吸入性糖皮质激素的患者，可选择按需使用布地奈德/福莫特罗（布地/福莫）。对于儿童轻度哮喘管理，每日吸入性糖皮质激素的首选以及反对间歇性短期吸入性糖皮质激素治疗的建议不变。
